Company Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.
Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease.
Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases.
The company was founded in 2013 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Feb 7, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 244 |
| CEO | Dr. Arnon Rosenthal Ph.D. |
Contact Details
Address: 131 Oyster Point Blvd., Suite 600 South San Francisco, California 94080 United States | |
| Phone | 415-231-5660 |
| Website | alector.com |
Stock Details
| Ticker Symbol | ALEC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001653087 |
| CUSIP Number | 014442107 |
| ISIN Number | US0144421072 |
| Employer ID | 82-2933343 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arnon Rosenthal Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Sara Kenkare-Mitra Ph.D. | President and Head of Research and Development |
| Dr. Marc Grasso M.D. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Gary Romano M.D., Ph.D. | Chief Medical Officer |
| Peter Heutink Ph.D. | Chief Scientific Officer |
| Katie Hogan | Senior Director of Corporate Communication and Investor Relations |
| Danielle Pasqualone J.D., Ph.D. | General Counsel |
| Clare Hunt M.B.A. | Chief People Officer |
| Kristina Cutter M.P.H. | Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer |
| Virginia DeJesus-Rueff M.B.A. | Chief of Staff and Head of Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Mar 1, 2024 | 144 | Filing |
| Feb 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |